To date, 18 clinical trials have been initiated to evaluate the therapeutic efficacy and safety of Dato-DXd in various solid tumors, including TNBC, HR-positive, HER2-low or -negative breast cancer (BC), and NSCLC. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.